Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreatic cancer
Authors:
- 7 June 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (10) , 1112-1121
Abstract
Background: In pancreatic cancer surgery, accurate identification and resection of intrapancreatic residual tumors are quite difficult. We have developed a novel open-typed PET system (called ‘OpenPET’), which enables high-resolution PET-guided surgery in real time, and demonstrated that OpenPET-guided surgery with intraperitoneally administered 64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab is useful to detect and resect primary pancreatic cancer. Here, we investigated applicability of OpenPET-guided surgery for unexpected residual intrapancreatic tumors and examined its survival benefit over conventional surgery. Methods: A mouse model with large (>1 cm) resectable pancreatic cancer of xPA-1-DC cells expressing red fluorescent protein was used. OpenPET-guided surgery was conducted 24 h after intraperitoneal administration of 64Cu-labeled cetuximab (7.4 MBq/mouse). For comparison, similar surgical procedures were conducted, and conventional tumor resection was attempted using only the naked eye (control). Survival rate after OpenPET-guided surgery was compared to that after control operations. Results: Intraoperative OpenPET guidance enabled detection and resection of small residual tumors. Ten residual tumor specimens (3–10 mm in diameter) were intraoperatively isolated with OpenPET guidance (n = 7 mice). All isolated specimens showed tumor RFP signals. No resection of tumor tissue was performed in control group because the tumor could not be clearly detected with the naked eye alone. Mice after OpenPET-guided surgery showed significantly longer survival rates than those in control group. Conclusions: OpenPET-guided surgery with 64Cu-labeled-cetuximab enabled intraoperative identification and resection of intrapancreatic small residual tumors. This technology could be useful to prevent tumor residuals during surgery and improve pancreatic cancer survival.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Novel Therapeutics for Pancreatic AdenocarcinomaHematology/Oncology Clinics of North America, 2015
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- A single-ring OpenPET enabling PET imaging during radiotherapyPhysics in Medicine & Biology, 2012
- Epidermal Growth Factor Receptor in Pancreatic CancerCancers, 2011
- Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinomaNuclear Medicine and Biology, 2011
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBritish Journal of Cancer, 2009
- Basic characterization of 64Cu-ATSM as a radiotherapy agentNuclear Medicine and Biology, 2005
- Copper-64-diacetyl-bis( N 4 -methylthiosemicarbazone): An agent for radiotherapyProceedings of the National Academy of Sciences, 2001
- Recurrence after resection for ductal adenocarcinoma of the pancreasWorld Journal of Surgery, 1997
- Aggressive surgery for pancreatic duct cell cancer: Feasibility, validity, limitationsWorld Journal of Surgery, 1995